Literature DB >> 17975024

Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis.

Zhirong Yin1, Lisa Williams-Simons, A F Parlow, Sylvia Asa, Lawrence S Kirschner.   

Abstract

Carney complex (CNC) is an inherited neoplasia syndrome characterized by spotty skin pigmentation, myxomas, endocrine tumors, and schwannomas. Among the endocrine tumors that comprise the syndrome, GH-producing pituitary tumors are seen in approximately 10% of patients, although biochemical abnormalities of the GH axis are much more common. To explore the role of loss of the CNC gene PRKAR1A on pituitary tumorigenesis, we produced a tissue-specific knockout (KO) of this gene in the mouse. For these studies, we generated a mouse line expressing the cre recombinase in pituitary cells using the rat GHRH receptor promoter. These mice were then crossed with Prkar1a conditional null animals to produce tissue-specific KOs. Although prolactinomas were observed in KO and control mice, the KO mice exhibited a significantly increased frequency of pituitary tumors compared with wild-type or conventional Prkar1a(+/-) mice. Characterization of the tumors demonstrated they were composed of cells of the Pit1 lineage that stained for GH, prolactin, and TSH. At the biochemical level, levels of GH in the serum of KO animals were markedly elevated compared with controls, regardless of the presence of a frank tumor. These data indicate that complete loss of Prkar1a is sufficient to allow the formation of pituitary tumors and abnormalities of the GH axis, in close analogy to human patients with CNC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975024      PMCID: PMC2234591          DOI: 10.1210/me.2006-0428

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  40 in total

1.  Effects of an Rb mutation in the mouse.

Authors:  T Jacks; A Fazeli; E M Schmitt; R T Bronson; M A Goodell; R A Weinberg
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

Review 2.  Molecular targets in pituitary tumours.

Authors:  Anthony P Heaney; Shlomo Melmed
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 3.  G-protein oncogenes in acromegaly.

Authors:  A Spada; L Vallar
Journal:  Horm Res       Date:  1992

4.  GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.

Authors:  C A Landis; S B Masters; A Spada; A M Pace; H R Bourne; L Vallar
Journal:  Nature       Date:  1989-08-31       Impact factor: 49.962

Review 5.  Mechanism of signal transduction by TRH.

Authors:  M C Gershengorn
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

6.  Of mice and MEN1: Insulinomas in a conditional mouse knockout.

Authors:  Judy S Crabtree; Peter C Scacheri; Jerrold M Ward; Sara R McNally; Gary P Swain; Cristina Montagna; Jeffrey H Hager; Douglas Hanahan; Helena Edlund; Mark A Magnuson; Lisa Garrett-Beal; A Lee Burns; Thomas Ried; Settara C Chandrasekharappa; Stephen J Marx; Allen M Spiegel; Francis S Collins
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

Review 7.  The prevalence of pituitary adenomas: a systematic review.

Authors:  Shereen Ezzat; Sylvia L Asa; William T Couldwell; Charles E Barr; William E Dodge; Mary Lee Vance; Ian E McCutcheon
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

8.  Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice.

Authors:  Mark Veugelers; David Wilkes; Kimberly Burton; Deborah A McDermott; Yan Song; Marsha M Goldstein; Krista La Perle; Carl J Vaughan; Art O'Hagan; Kenneth R Bennett; Beat J Meyer; Eric Legius; Mervi Karttunen; Reijo Norio; Helena Kaariainen; Michael Lavyne; Jean-Philippe Neau; Gert Richter; Kaan Kirali; Alan Farnsworth; Karen Stapleton; Peter Morelli; Yoshinori Takanashi; John-Steven Bamforth; Franz Eitelberger; Irene Noszian; Waldimiro Manfroi; James Powers; Yoshihiko Mochizuki; Tsuneo Imai; Gary T C Ko; Deborah A Driscoll; Elizabeth Goldmuntz; Jay M Edelberg; Amanda Collins; Diana Eccles; Alan D Irvine; G Stanley McKnight; Craig T Basson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-15       Impact factor: 11.205

9.  Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.

Authors:  L S Weinstein; A Shenker; P V Gejman; M J Merino; E Friedman; A M Spiegel
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

10.  Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development.

Authors:  Jeannette Philipp-Staheli; Kyung-Hoon Kim; Denny Liggitt; Kay E Gurley; Gary Longton; Christopher J Kemp
Journal:  Oncogene       Date:  2004-01-29       Impact factor: 9.867

View more
  29 in total

Review 1.  PRKAR1A and the evolution of pituitary tumors.

Authors:  Lawrence S Kirschner
Journal:  Mol Cell Endocrinol       Date:  2010-05-06       Impact factor: 4.102

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 3.  Familial pituitary tumor syndromes.

Authors:  Marianne S Elston; Kerrie L McDonald; Roderick J Clifton-Bligh; Bruce G Robinson
Journal:  Nat Rev Endocrinol       Date:  2009-06-30       Impact factor: 43.330

Review 4.  Phosphodiesterase 8B and cyclic AMP signaling in the adrenal cortex.

Authors:  Leticia Ferro Leal; Eva Szarek; Fabio Faucz; Constantine A Stratakis
Journal:  Endocrine       Date:  2015-05-14       Impact factor: 3.633

Review 5.  Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes.

Authors:  Fausto J Rodriguez; Constantine A Stratakis; D Gareth Evans
Journal:  Acta Neuropathol       Date:  2011-12-31       Impact factor: 17.088

6.  A heritable predisposition to pituitary tumors.

Authors:  William T Couldwell; Lisa Cannon-Albright
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

7.  Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling.

Authors:  Madson Q Almeida; Michael Muchow; Sosipatros Boikos; Andrew J Bauer; Kurt J Griffin; Kit Man Tsang; Chris Cheadle; Tonya Watkins; Feng Wen; Matthew F Starost; Ioannis Bossis; Maria Nesterova; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2010-01-15       Impact factor: 6.150

8.  Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice.

Authors:  Isabelle Sahut-Barnola; Cyrille de Joussineau; Pierre Val; Sarah Lambert-Langlais; Christelle Damon; Anne-Marie Lefrançois-Martinez; Jean-Christophe Pointud; Geoffroy Marceau; Vincent Sapin; Frédérique Tissier; Bruno Ragazzon; Jérôme Bertherat; Lawrence S Kirschner; Constantine A Stratakis; Antoine Martinez
Journal:  PLoS Genet       Date:  2010-06-10       Impact factor: 5.917

Review 9.  cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.

Authors:  Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-02-26       Impact factor: 4.102

10.  Cyclic nucleotide signaling in polycystic kidney disease.

Authors:  Xiaofang Wang; Christopher J Ward; Peter C Harris; Vicente E Torres
Journal:  Kidney Int       Date:  2009-11-18       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.